Cargando…

CDK4/6 inhibition: the late harvest cycle begins

Detalles Bibliográficos
Autores principales:	Goel, Shom, Zhao, Jean J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226473/ https://www.ncbi.nlm.nih.gov/pubmed/27391058 http://dx.doi.org/10.18632/oncotarget.9576

Ejemplares similares

CDK4/6 inhibition in breast cancer: current practice and future directions
por: Pernas, Sonia, et al.
Publicado: (2018)

Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
por: Watt, April C., et al.
Publicado: (2022)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

CDK4/6 inhibition triggers anti-tumor immunity
por: Goel, Shom, et al.
Publicado: (2017)

Unexpected Outcomes of CDK4/6 Inhibition
por: Choi, Yoon Jong, et al.
Publicado: (2013)

PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023)

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
por: Wander, Seth A, et al.
Publicado: (2022)

Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023)

CDK4/6 inhibition in cancer: the cell cycle splicing connection
por: Sheppard, Karen E., et al.
Publicado: (2019)

Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breast cancer cells
por: Blain, Stacy W.
Publicado: (2018)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature
por: David, Steven, et al.
Publicado: (2020)

CDK1: beyond cell cycle regulation
por: Liao, Hongwei, et al.
Publicado: (2017)

Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition
por: Hu, Qingyi, et al.
Publicado: (2023)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

CDK4/6 inhibition protects normal cells against cancer therapy-induced damage
por: Boopathi, Ettickan, et al.
Publicado: (2020)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib
por: Böhm, Michael J., et al.
Publicado: (2019)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

Sulforaphane-cysteine downregulates CDK4 /CDK6 and inhibits tubulin polymerization contributing to cell cycle arrest and apoptosis in human glioblastoma cells
por: Li, Juntao, et al.
Publicado: (2020)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
por: Piezzo, Michela, et al.
Publicado: (2020)

The Beginning
por: Dogra, Vikram
Publicado: (2011)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

THE BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY COMPLETES 35 YEARS AND A NEW CYCLE BEGINS
por: ANDREOLLO, Nelson Adami, et al.
Publicado: (2022)

CDK6 and p16(INK4A) in lymphoid malignancies
por: Kollmann, Karoline, et al.
Publicado: (2013)

Trastuzumab-related cardiotoxicity: what do we know in 2020?
por: Liu, Jia, et al.
Publicado: (2020)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Endings and beginnings
por: Ombelet, W
Publicado: (2016)

New Beginnings
por: Wang, Jeffrey C., et al.
Publicado: (2020)

New beginnings
por: Kühnel, Karin
Publicado: (2022)

New Beginnings
por: “Sam” Samaranayake, Lakshman
Publicado: (2022)

p18 inhibits reprogramming through inactivation of Cdk4/6
por: Zhu, Shaohua, et al.
Publicado: (2016)

Let the Journey Begin
por: Brilli, Richard J., et al.
Publicado: (2016)

Inhibition of Mitochondrial Antioxidant Defense and CDK4/6 in Mesothelioma
por: Kratzke, Marian, et al.
Publicado: (2023)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition
por: Kim, Sungsoo, et al.
Publicado: (2022)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Thoughts at the beginning of the term
por: Sinescu, I
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rtjn0j9m4roqe5viplp4rnp5m4